Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

Ma, Angela; Thompson, L. Alexa; Corsiatto, Thomas; Hurteau, Donna; Tyrrell, Gregory J.

doi:10.1128/spectrum.01283-21

Cited by 8 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we characterized serotype VIII GBS isolates identified in Alberta from January 2003 to September 2021 [ 14 , 16 ]. The goal was to characterize this emerging group within Alberta primarily through genomic analyses, as there are no previous genome-based studies focused on this group to the best of our knowledge.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, antimicrobial resistance was limited, with only one isolate exhibiting erythromycin and inducible clindamycin resistance (Table 1 ). Alberta has seen increases in resistance to erythromycin and clindamycin among invasive GBS, especially among adult isolates [ 14 ]. In a study comparing changes in resistance rates among GBS isolates in Alberta between 2003–2013 and 2014–2020, erythromycin non-susceptibility rose from 36.9 to 50.8% and clindamycin non-susceptibility rose from 21.0 to 45.8% between the two time periods [ 14 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Neonatal invasive GBS disease is listed as a notifiable disease in Alberta requiring GBS isolates to be submitted to the Alberta Public Health Laboratory for capsular polysaccharide (CPS) typing and antimicrobial susceptibility testing [ 14 ]. For other age groups, clinical microbiology laboratories in Alberta submit invasive GBS isolates to the Public Health Laboratory for CPS typing as a part of an ongoing passive surveillance program.…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…From 2014 to 2020 in Alberta, Canada, the most prevalent serotypes of invasive GBS in order of prevalence were III, Ia, Ib, II, V, IV, and VI [ 14 , 16 ]. During this period, seven cases of invasive serotype VIII were identified (0.45% of the total cases), which was more than double seen in a previous study that identified 3 cases (0.2% of total cases) from 2003 to 2013 [ 14 , 16 ]. In this work, we characterized these emerging invasive serotype VIII isolates in Alberta collected over the period of January 2003 to September 2021 by determining the multilocus sequence types (ST), antimicrobial resistance and virulence factor carriage, phylogenetic relationships, and pangenome of these isolates.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Genomic characterization of emerging invasive Streptococcus agalactiae serotype VIII in Alberta, Canada

Williams

Croxen

Demczuk

et al. 2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Invasive Group B Streptococcus (GBS) can infect pregnant women, neonates, and older adults. Invasive GBS serotype VIII is infrequent in Alberta; however, cases have increased in recent years. Here, genomic analysis was used to characterize fourteen adult invasive serotype VIII isolates from 2009 to 2021. Trends in descriptive clinical data and antimicrobial susceptibility results were evaluated for invasive serotype VIII isolates from Alberta. Isolate genomes were sequenced and subjected to molecular sequence typing, virulence and antimicrobial resistance gene identification, phylogenetic analysis, and pangenome determination. Multilocus sequencing typing identified eight ST42 (Clonal Complex; CC19), four ST1 (CC1), and two ST2 (CC1) profiles. Isolates were susceptible to penicillin, erythromycin, chloramphenicol, and clindamycin, apart from one isolate that displayed erythromycin and inducible clindamycin resistance. All isolates carried genes for peptide antibiotic resistance, three isolates for tetracycline resistance, and one for macrolide, lincosamide, and streptogramin resistance. All genomes carried targets currently being considered for protein-based vaccines (e.g., pili and/or Alpha family proteins). Overall, invasive GBS serotype VIII is emerging in Alberta, primarily due to ST42. Characterization and continued surveillance of serotype VIII will be important for outbreak prevention, informing vaccine development, and contributing to our understanding of the global epidemiology of this rare serotype. Supplementary Information The online version contains supplementary material available at 10.1007/s10096-023-04606-9.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Genomic characterization of emerging invasive Streptococcus agalactiae serotype VIII in Alberta, Canada

Williams

Croxen

Demczuk

et al. 2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

Incidence of invasive infections with Group B streptococcus in adults in Norway 1996–2019: a nationwide registry-based case–control study

Uggen,

Olaisen,

Lyng

et al. 2024

Infection

View full text Add to dashboard Cite

Purpose Group B streptococcus (GBS) colonizes the gastrointestinal and vaginal mucosa in healthy adults, but has also become an increasing cause of invasive infection. The aims of this study were to describe the incidence and factors associated with the occurrence of invasive GBS disease in adults in Norway. Methods We performed a nationwide retrospective case–control study of invasive GBS infections during 1996–2019, with two control groups; invasive Group A streptococcal disease (GAS) to control for changes in surveillance and diagnostics, and a second representing the general population. Results A total of 3710 GBS episodes were identified. The age-standardized incidence rate increased steadily from 1.10 (95% CI 0.80–1.50) in 1996 to 6.70 (95% CI 5.90–7.50) per 100,000 person-years in 2019. The incidence rate had an average annual increase of 6.44% (95% CI 5.12–7.78). Incidence rates of GAS varied considerably, and there was no evidence of a consistent change over the study period. GBS incidence was highest among adults > 60 years of age. Cardiovascular disease, cancer, and diabetes were the most common comorbid conditions. There was a shift in the distribution of capsular serotypes from three dominant types to more equal distribution among the six most common serotypes. Conclusions The incidence of invasive GBS disease in adults increased significantly from 1996 to 2019. The increasing age of the population with accompanying underlying comorbid conditions might contribute to the increasing burden of invasive GBS disease. Interestingly, type 1 diabetes was also associated with the occurrence of invasive GBS disease.

show abstract

Group B Streptococcus in Pregnancy

Mei

Silverman

2023

Obstetrics and Gynecology Clinics of North America

View full text Add to dashboard Cite

Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

Cited by 8 publications

References 61 publications

Genomic characterization of emerging invasive Streptococcus agalactiae serotype VIII in Alberta, Canada

Genomic characterization of emerging invasive Streptococcus agalactiae serotype VIII in Alberta, Canada

Incidence of invasive infections with Group B streptococcus in adults in Norway 1996–2019: a nationwide registry-based case–control study

Group B Streptococcus in Pregnancy

Contact Info

Product

Resources

About